PRMT5 is a therapeutic target in choroidal neovascularization

PRMT5 is a therapeutic target in choroidal neovascularization

Abstract Ocular neovascular diseases including neovascular age-related macular degeneration (nvAMD) are widespread causes of blindness. Patients’ non-responsiveness to currently used biologics that target vascular endothelial growth factor (VEGF) poses an unmet need for novel therapies. Here, we ide...

Full description

Bibliographic Details
Main Authors: Anbukkarasi Muniyandi, Matthew Martin, Kamakshi Sishtla, Aishat Motolani, Mengyao Sun, Nathan R. Jensen, Xiaoping Qi, Michael E. Boulton, Lakshmi Prabhu, Tao Lu, Timothy W. Corson
Format: Article
Language:English
Published: Nature Portfolio 2023-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-28215-w

Internet

https://doi.org/10.1038/s41598-023-28215-w

Similar Items